Product Specification Sheet

Product Name:TMC207 (Bedaquiline)Catalog Number:C8207Technical information:C_2,H2aN2O3CAS #:843663-66-1Molecular Weight:555.5Purity:> 98%Appearance:white solidSolubility:Solubion, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.Biological Activity:TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial B at an MIC range of 2 to 60 nM and an MICS0 of 30 ng/mL. Additionally TMC207 is broally potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1)Studies show that TMC207: the first compoud of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 205219312. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207. The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 205219312. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207.				
Technical information:Chemical Formula: $C_{24}H_{28}N_2O_3$ $CAS #: 843663-66-1$ Molecular Weight:555.5Purity:>98%Appearance:white solidSolubility:Storage:For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.Shelf Life:In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.Handling:• To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline).• For DMSO Solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.Biological Activity:TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial Raperiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1)Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2)Reference:1. Matteellit et al., TMC207: the first compound of a new class	Product Name:	TMC207 (Bedaquiline)		
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Catalog Number:	C8207		
CAS #: 843663-66-1 Molecular Weight: 555.5 Purity: > 98% Appearance: white solid Solubility: Soluble in DMSO up to 2 mM Chemical Name: (18,25)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2.	Technical information:			
Molecular Weight: 555.5 Purity: > 98% Appearance: white solid Solubility: Solubile in DMSO up to 2 mM Chemical Name: (1R,25)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial Paperiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericial Activity and Pharmacokinetics of the Diarylquinoline TMC207, its researce of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852	Chemical Formula:	$C_{24}H_{28}N_2O_3$		
Purity: > 98% TMC207 (Bedaquiline) Solubility: Soluble in DMSO up to 2 mM Chemical Name: (IR,25)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquillen). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-888. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: htttp://wwww.cellagentech.com/TMC207-Bedaquiline/	CAS #:	843663-66-1		
Appearance: white solid (Bedaquiline) Solubility: Solubile in DMSO up to 2 mM Chemical Name: (1R,25)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial reperiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MICS0 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 5	Molecular Weight:	555.5	Br	
Solubility: Solubility: Solubility: Solubility: Solubility: Solubility: Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MICS0 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: htttp://www.cellagente	Purity:	> 98%	TMC207	
Chemical Name: (1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1- Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compoudn of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Appearance:	white solid	(Bedaquiline)	
Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated. Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Solubility:	Soluble in DMSO up to 2 mM		
Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition. Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Chemical Name:	(1R,2S)-1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-(naphthalen-1-yl)-1-		
under proper storage condition. Handling: To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compoudn of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Storage:	For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.		
Handling: • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaquiline). • For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Shelf Life:	In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months		
 For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/ 		under proper storage condition.		
 For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/ 	Handling • To make 2 mM stock solution, add 0.9mL of DMSO for each mg of TMC207 (Bedaguiline).			
sample recovery. Biological Activity: TMC207 (Bedaquiline) is a diarylquinoline-based inhibitor of bacterial ATP synthase at nanomolar concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/				
 concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for patients with pulmonary TB. No serious adverse events were observed. (2) Reference: 1. Matteelli et al., TMC207: the first compoudn of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/ 				
Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835. Pubmed ID: 18505852 To reorder: http://www.cellagentech.com/TMC207-Bedaquiline/	Biological Activity:	concentrations. In vitro mycobacterial experiments show that TMC207 inhibits drug-sensitive and drug-resistant mycobacterial TB at an MIC range of 2 to 60 nM and an MIC50 of 30 ng/mL. Additionally TMC207 is broadly potent against many non-tuberculous mycobacteria, with MICs of 6 to 500 nM. (1) Studies show that TMC207 is orally-available and efficacious on a once-daily administration for		
	Microbiol. 2010, 5(6), 849-858. Pubmed ID: 20521931 2. Rustomjee et al., Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis. Antimicrob. Agents Chemother. 2008, 52(8), 2831-2835.			
	To reorder:	http://www.cellagentech.com/TMC207-Bedac	quiline/	

Chemicals are sold for research use only, not for clinical or diagnostic use.